Back to today’s briefing

Story perspectives

GeneDx Surpasses Revenue Expectations, Shares Plunge 39.3%

5/2/2025

45 5

Summary

Story summary

GeneDx's Q1 revenue hit $87.1 million, surpassing expectations by 10%, yet it left investors wanting more as test volumes dipped for the first time since its IPO. In a surprising twist, the company boosted its annual sales forecast to $360-$375 million, showcasing its growth potential in genetic testing, but shares plummeted by 39.3%.

1 of 1

Story summary

GeneDx's Q1 revenue hit $87.1 million, surpassing expectations by 10%, yet it left investors wanting more as test volumes dipped for the first time since its IPO. In a surprising twist, the company boosted its annual sales forecast to $360-$375 million, showcasing its growth potential in genetic testing, but shares plummeted by 39.3%.